REINHARDT MAX 4
4 · Pacira BioSciences, Inc. · Filed Apr 25, 2022
Insider Transaction Report
Form 4
REINHARDT MAX
President
Transactions
- Exercise/Conversion
Common Stock
2022-04-21$42.54/sh+12,500$531,750→ 39,474 total - Sale
Common Stock
2022-04-21$73.25/sh−9,824$719,647→ 29,650 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-04-21−12,500→ 100,000 totalExercise: $42.54Exp: 2029-07-02→ Common Stock (12,500 underlying)
Footnotes (3)
- [F1]The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
- [F2]Represents shares sold by the reporting person to cover the (i) exercise price of stock options and (ii) tax obligations due upon the exercise of such stock options.
- [F3]The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.